Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study reported that an alkaloid isolated from E. alba leaves inhibited HIV-1 reverse transcriptase activity with minimal cytotoxicity, suggesting its potential as an antiviral agent.

This study reported that patients with alopecia areata treated with ritlecitinib in a real-life setting had a higher rate of positive response on the Severity of Alopecia Tool score compared to those in the ALLEGRO trial.

In this study, researchers at Jawaharlal Nehru Medical College are comparing the effectiveness and side effects of Adapalene gel (0.1%) and Tazarotene gel (0.05%) in acne treatment among patients aged 12-35, with assessments every 4, 8, and 12 weeks. Results are not reported yet.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

This article reviews the various short- and long-term side effects of antiretroviral therapy for HIV, highlighting issues like dyslipidemia and hypertension, but reports no new clinical results.

This case report presents an HIV-1 patient who experienced osteosclerosis and new bone formation potentially due to long-term indinavir therapy and concurrent use of vitamin A, with symptoms reducing after switching to nelfinavir.

This article reviews treatment-induced sexual dysfunctions related to 5-alpha-reductase inhibitors and reports no new results; it highlights the need to better define and understand this controversial topic.

In this study, the authors reported that dutasteride significantly reduced total remission time for COVID-19 symptoms in men compared to placebo, especially for fatigue and loss of taste or smell.

This study found that Ritlecitinib significantly reduced hair loss in patients with alopecia areata by lowering SALT scores at weeks 12 and 24 compared to placebo, with acceptable safety but increased minor side effects like headaches and acne.

This meta-analysis reported that the use of 5α-reductase inhibitors significantly increased the risk of postfinasteride syndrome-like adverse effects in men treated for benign prostatic hyperplasia or androgenetic alopecia.

This article describes the development milestones and recent approvals of ritlecitinib for treating severe alopecia areata, with approvals in the USA and Japan and ongoing regulatory reviews in other regions.

In this review, the authors highlight the FDA approval of Ritlecitinib, the first oral treatment specifically for moderate to severe alopecia areata in patients aged 12 and older, marking a significant advancement in managing this condition.

This review highlights that 5 Alpha Reductase Inhibitors, used for treating conditions like benign prostatic hypertrophy, can cause side effects that sometimes persist after stopping the medication, urging physicians to consider these drugs as potential sources of new symptoms in patients.

Men using 5-alpha reductase inhibitors for prostate issues may have a slightly higher risk of blood clots.

This review discusses the pharmacology of 5-alpha reductase inhibitors, their expanding clinical indications beyond benign prostatic hyperplasia, and notes unresolved claims about their potential role in SARS-CoV-2.

This study found that daily treatment with ritlecitinib 50 mg over 24 months reduced the number of patients in the highest categories of scalp hair loss, with improvements seen in patient responses over time.

This study found that GI198745 acts as a time-dependent inhibitor of rat 5α-reductase type 2 but a rapid-equilibrium inhibitor of type 1, potentially making it more effective than finasteride in preventing rat prostate growth.

This study evaluated the effectiveness and safety of ritlecitinib in patients aged 12 or older with alopecia totalis or universalis, finding higher hair regrowth response rates compared to placebo at 24 weeks, with continued improvement and acceptable safety through 48 weeks.

This study reported no significant difference in efficacy or sexual dysfunction risk between 5α-reductase inhibitors and placebo for androgenetic alopecia, suggesting that dutasteride 0.5 mg may be considered pending further research.

In this retrospective, population-based cohort study, researchers found no significant difference in age-related macular degeneration incidence between BPH patients using 5α-reductase inhibitors and those on tamsulosin, but observed a slight increased risk with dutasteride compared to finasteride.

Agomelatine might help reduce hair loss caused by valproate.

This study found that while 5α-reductase inhibitors like finasteride had many serious, unresolved adverse drug reactions, some were not listed in the existing product information.

Gepant medications for migraines show varied safety profiles in this study, with specific adverse events reported across systems like gastrointestinal and skin disorders, highlighting the need for tailored treatment and monitoring.

Ritlecitinib helps adolescents with severe alopecia areata regrow scalp hair and normalize body hair and nails.

Using hair loss drugs finasteride and dutasteride may cause sexual side effects.

This source highlights that topical retinoids, particularly adapalene and its combinations, are crucial in treating acne due to their rapid action, sustained effects, and good tolerability; the study underscores the enhanced patient adherence with Deriva C MS gel for acne treatment.

This study found that valproate sustained-release monotherapy provided effective short-term seizure control and was well tolerated in newly-diagnosed epileptic patients with partial seizures in the Gulf Cooperation Council countries.

This review found that dutasteride is more potent than finasteride as a dual receptor dihydrotestosterone blocker for treating androgenetic alopecia and shares a similar safety profile in terms of fertility, teratogenicity, neurotoxicity, and hepatotoxicity.

Men with hair loss who take a certain type of medication may experience fewer COVID-19 symptoms.